Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a lab notebook. Tenaya Therapeutics鈥� disclosures dive deep into AAV capsid engineering, clinical trial design, and cash runway assumptions鈥攄etails that matter when therapies aim to cure inherited cardiomyopathies. If you have ever searched, 鈥淭enaya Therapeutics SEC filings explained simply鈥� or wondered how a single 8-K might impact dilution risk, you know the challenge.
Stock Titan solves it. Our AI parses every Tenaya Therapeutics annual report 10-K simplified, flags pipeline milestones in each 10-Q, and delivers real-time alerts the moment a Tenaya Therapeutics Form 4 insider transactions real-time notice hits EDGAR. You will see at a glance who bought shares, how R&D spend shifted, and what FDA feedback appeared in the latest 8-K material events explained. Need the numbers fast? The platform auto-builds tables that compare quarter-over-quarter trial expenses and manufacturing capital needs鈥攏o more hunting through footnotes.
Use cases professionals rely on daily include:
- Monitoring Tenaya Therapeutics executive stock transactions Form 4 ahead of material data readouts
- Reviewing a Tenaya Therapeutics quarterly earnings report 10-Q filing for cash-burn trends
- Extracting pay packages from a Tenaya Therapeutics proxy statement executive compensation section
- Running a Tenaya Therapeutics earnings report filing analysis to benchmark pipeline progress
With comprehensive coverage of every filing type鈥�10-K, 10-Q, 8-K, S-3, and more鈥攑lus AI-powered summaries that translate scientific jargon into plain language, understanding Tenaya Therapeutics SEC documents with AI becomes straightforward. Stay current, save hours, and make informed decisions with data that updates the instant Tenaya Therapeutics insider trading Form 4 transactions are filed.
Empery Asset Management, LP and its principals Ryan M. Lane and Martin D. Hoe filed Amendment No. 1 to Schedule 13G, disclosing a passive ownership of 8,296,276 Tenaya Therapeutics (TNYA) shares. The holding equals 4.99 % of the 162,666,931 shares outstanding as of 1 May 2025, keeping the group just below the 5 % threshold.
The position is split between 4,705,164 common shares already owned and 3,591,112 shares issuable via warrants. These warrants contain a 4.99 % 鈥渂locker,鈥� preventing exercise that would push total ownership above the cap; therefore not all warrants are currently exercisable. All voting and dispositive power is shared; none of the reporting persons holds sole authority.
The filing states the securities were acquired in the ordinary course of business and not for the purpose of influencing control. While the stake signals continued institutional interest, the blocker-constrained warrants represent potential future dilution if exercised once ownership falls below the limit.
FAQ
What is the current stock price of Tenaya Therapeutics (TNYA)?
What is the market cap of Tenaya Therapeutics (TNYA)?
What is the core mission of Tenaya Therapeutics?
Which therapeutic platforms does Tenaya employ?
How does Tenaya differentiate itself from other cardiovascular treatment approaches?
What technologies support Tenaya鈥檚 gene therapy programs?
What is the significance of in-house manufacturing for Tenaya?
Who are the typical stakeholders or customers for Tenaya鈥檚 innovations?
How does Tenaya ensure scientific rigor in its research and development?
What role does precision medicine play in Tenaya's portfolio?
